Darunavir/ritonavir in Pregnancy

PANNA Trial
Darunavir/r in Pregnancy
PANNA: Study Design

Study Design: PANNA Network

• **Background**: Open-label, nonrandomized, phase 4 trial to describe the pharmacokinetics of darunavir in pregnant HIV-infected women during the third trimester and postpartum

• **Inclusion Criteria (n = 24)**
  - Age ≥18
  - Taking darunavir + ritonavir ≥2 weeks prior to initial assessment in 3rd trimester of pregnancy

• **Treatment Arm***
  - Darunavir + ritonavir + optimized background therapy

* **Dosing regimens (n= # of women)**
  - Darunavir 600 mg BID + Ritonavir 100 mg BID (n=6)
  - Darunavir 800 mg QD + Ritonavir 100 mg QD (n=17)
  - Darunavir 600 mg QD + Ritonavir 100 mg QD (n=1)

Darunavir/r in Pregnancy

PANNA: Result

Virologic Suppression Close to Delivery

Darunavir/r in Pregnancy
PANNA: Result

Pregnancy Outcomes

- Small for gestational age (SGA): 17%
- Low birth weight (< 2500g): 25%
- HIV-infected: 0%

Darunavir/r in Pregnancy
PANNA: Result

Darunavir Pharmacokinetic Parameters

Conclusions: “Darunavir AUC and Cmax were substantially decreased in pregnancy for both darunavir/ritonavir regimens. This decrease in exposure did not result in mother-to-child transmission. For antiretroviral-naive patients, who are adherent, take darunavir with food and are not using concomitant medication reducing darunavir concentrations, 800/100 mg of darunavir/ritonavir once daily is adequate in pregnancy. For all other patients 600/100 mg of darunavir/ritonavir twice daily is recommended during pregnancy.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.